ROCKVILLE, Md., April 15, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will review recent clinical results from the company's vaccine development programs at the World Vaccine Congress and Expo this week in Washington, DC. On April 16 at 5:55pm (ET) during the session on prophylactic vaccines, Dr. Gregory Glenn, Novavax' Senior Vice President and Chief Medical Officer, will discuss results from the company's respiratory syncytial virus (RSV) nanoparticle vaccine development program, including recently announced positive results from a Phase II clinical trial in women of childbearing age. In that trial, Novavax' vaccine candidate was well-tolerated and demonstrated sufficient immunogenicity with and without aluminum phosphate as an adjuvant to support plans for later-stage clinical testing. The company believes its RSV vaccine candidate has the potential to induce functional immune responses at levels that may protect infants through maternal immunization. On April 17 at noon (ET) during the session on influenza vaccines, Dr. Louis Fries, Novavax' Vice President, Clinical and Medical Affairs, will review results from the company's virus-like particle pandemic H5N1 influenza vaccine clinical program. In a recent Phase I clinical trial, Novavax' vaccine candidate was well-tolerated and demonstrated sufficient immunogenicity at multiple dose levels with and without an adjuvant to support advancement into Phase II testing. The company believes its Phase I findings suggest that the adjuvanted vaccine candidate could provide antigen dose sparing and strong immune responses to the targeted virus. About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax' worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com . Forward-Looking Statements Statements herein relating to the future of Novavax and its ongoing development of its VLP vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2012, and filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
CONTACT: Frederick W. Driscoll VP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000